Last 16 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.00 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 3.12 | 3.60 | 6.36 | 3.49 | 2.60 | 4.17 | 1.32 | 1.22 | 18.90 | — | — | — | — |
| — | -13.8% | +382.8% | +186.5% | -86.2% | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.00 | 1.30 | 0.46 | 0.31 | 0.77 | 0.17 | 0.10 | — | 3.15 | 0.88 | 1.37 | 0.86 | 0.75 |
| — | +682.5% | +338.2% | — | -75.5% | -81.1% | -92.4% | — | +319.7% | -8.1% | +10.7% | -96.0% | — | |
| P/FCF | — | — | — | — | — | — | — | — | 0.63 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Onconetix, Inc.'s operating margin was -681.5% in Q3 2025, up 1135.9 pp QoQ and down 31.1 pp YoY. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of -4740.4% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 241.8% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 41.8% | 88.6% | 66.2% | 45.1% | 92.7% | 25.9% | 14.3% | 27.0% | -1941.8% | — | — | — | — |
| — | +241.8% | +363.3% | +67.1% | +104.8% | — | — | — | — | — | — | — | — | |
| Operating Margin | -2238.0% | -681.5% | -1817.4% | -12369.2% | -4093.7% | -650.3% | -1931.6% | -1582.2% | -9226.6% | — | — | — | — |
| — | -4.8% | +5.9% | -681.8% | +55.6% | — | — | — | — | — | — | — | — | |
| Net Margin | -2325.2% | -2892.7% | -2227.8% | -8408.8% | -4134.7% | -940.7% | -2029.8% | -1587.4% | -38229.5% | — | — | — | — |
| — | -207.5% | -9.8% | -429.7% | +89.2% | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -1065.7% | -189.2% | -45.5% | -121.0% | -116.3% | -10.0% | -136.2% | — | -384.0% | -45.9% | -41.9% | -13.5% | -13.4% |
| — | -1791.8% | +66.6% | — | +69.7% | +78.2% | -225.0% | — | -2771.0% | -174.7% | -82.3% | +41.3% | +83.9% | |
| ROA | -101.5% | -45.3% | -12.5% | -36.4% | -65.3% | -6.3% | -21.3% | -13.7% | -38.7% | -18.6% | -26.3% | -11.7% | -11.4% |
| — | -618.0% | +41.1% | -166.1% | -68.7% | +66.0% | +19.0% | -17.3% | -239.9% | -29.1% | -32.4% | +36.9% | +70.8% | |
| ROIC | -336.9% | -18.2% | -11.0% | -62.0% | -63.2% | -3.9% | -44.1% | -523.5% | -36.4% | -20.7% | -30.6% | — | — |
| — | -360.8% | +75.0% | +88.1% | -73.6% | +81.0% | -44.3% | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 32.3% YoY to 0.08x, strengthening the short-term liquidity position. Debt/Equity has declined for 3 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.98 | 0.05 | 1.48 | 2.00 | 0.98 | 0.25 | 0.43 | — | 7.04 | 1.26 | 1.01 | — | — |
| — | -80.0% | +244.2% | — | -86.0% | -80.5% | -57.2% | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 0.05 | 0.08 | 0.07 | 0.17 | 0.05 | 0.06 | 0.10 | 0.29 | 0.34 | 0.54 | 0.94 | 7.87 | 6.69 |
| — | +32.3% | -25.8% | -41.3% | -84.7% | -88.8% | -89.5% | -96.3% | -94.9% | -92.0% | -87.6% | +16.9% | +373.6% | |
| Quick Ratio | 0.05 | 0.07 | 0.06 | 0.16 | 0.05 | 0.05 | 0.09 | 0.28 | 0.32 | 0.46 | 0.84 | 7.87 | 6.69 |
| — | +32.3% | -32.7% | -41.4% | -84.8% | -88.4% | -89.2% | -96.5% | -95.2% | -93.2% | -88.9% | +16.9% | +373.6% | |
| Interest Coverage | -40.13 | -6.90 | -8.68 | -56.22 | -117.36 | -6.87 | -37.68 | -26.83 | -28.61 | -16.68 | -14.72 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 16 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonOnconetix, Inc.'s current P/E is -0.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Onconetix, Inc.'s current operating margin is -2238.0%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Onconetix, Inc.'s business trajectory between earnings reports.